Takeda Pharmaceutical Co.

TAK

Healthcare Drug Manufacturers Specialty & Generic

Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.

Revenue
+1.71%
EPS
−4.35%
Free cash flow
+54.9%
Total debt
−7.28%

Quarter to September 2026, against a year earlier

21.43 0.31 +1.47%
Market cap
$67.5B
P/E
32.3×
Fwd P/E
—
Dividend yield
1.44%
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
5.8×
Dividend safety
25/100
Older periods Sep '25 Dec '25 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

— — 6 —
ROE
0.00% 0.00% 4.42% 0.00%
ROA
0.00% 0.00% 2.15% 0.00%
ROIC
0.00% 0.00% 2.88% 0.00%
Return on Tangible Assets
0.00% 0.00% 13.40% 0.00%
Average Days of Receivables
0.00 0.00 73.31 0.00
Free Cash Flow per Share
0.00 0.00 2.35 0.00
Free Cash Flow
8,314.41 10,878.22 7,420.86 7,976.47
Capital Expenditures
(3,167.12) (4,954.63) (3,704.87) (3,579.71)
Other line items
Cash ROIC
9.77% 12.62% 9.04% 10.17%
Accounts Receivable Turnover
0.00 0.00 5.52 0.00
Accounts Payable Turnover
0.00 0.00 3.50 0.00
Inventory Turnover
0.00 0.00 1.18 0.00
Average Days of Payables
0.00 0.00 100.31 0.00
Days of Inventory on Hand
0.00 0.00 324.95 0.00
Tax Rate
— — (0.17) —
Research and Development Expense of Revenue
— — 14.77% —
Selling, General and Administrative Expense of Revenue
— — 23.99% —
Share Based Compensation of Revenue
0.00% 0.00% 2.33% 0.00%
Interest Coverage
— — 1.99 —
Operating CF/Net income
0.00 0.00 5.21 0.00
Depreciation/Fixed assets
0.56 0.73 0.53 0.48
Capex/Depreciation
(0.42) (0.50) (0.52) (0.52)
Revenue per Share
— — 9.49 —
Operating CF per Share
0.00 0.00 3.52 0.00
Capex per Share
0.00 0.00 (1.17) 0.00
Capex to Sales
0.00 0.00 0.12 0.00

Fold the line items

Columns are period end dates · fundamentals updated 2 Nov 2026